跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
Money, Incentives, and the Business of Drug Development

Why a promising AI drug can still be dropped

4 / 4
Notice that none of these four reasons is about whether the molecule works. Novelty makes the risk harder to price. A thin evidence base makes funders wait. A conventional competitor already further along raises the bar. And a cheap early design does not help if the expensive stages after it are unchanged. Together they mean an AI-originated candidate has to clear a higher bar than a conventional one to get the same funding. That is how a drug can be real, published, and still never reach a patient.
0:00 / 0:00

Why the bar is higher for an AI-originated candidate

  • Novelty raises perceived risk, which lowers the probability term in the expected return.
  • A thinner evidence base makes the risk harder to price, so funders may wait for more data.
  • A conventional competitor already further along forces the AI candidate to be clearly better to displace it.
  • A cheap early design does not help if the expensive later stages are unchanged.

Being dropped is not a verdict on the molecule. It is a verdict on the project's risk-adjusted return — and that verdict can be reached before any patient is ever involved.

上一页4 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion